Autologous stem cells are collected from the patient's own body, commonly from bone marrow, adipose tissue or peripheral blood. Because the cells come from the same person, donor compatibility is not required. Collection procedures, processing time and suitability vary depending on the selected cell source.

Allogeneic stem cells are obtained from a screened donor rather than from the patient. Potential sources may include umbilical cord tissue, Wharton's Jelly, placenta, amniotic tissue or cord blood. Donor screening, laboratory processing and product quality documentation should be reviewed before treatment.

Umbilical cord MSCs are donor-derived mesenchymal stromal cells obtained from donated birth tissue after delivery. They are commonly discussed in regenerative medicine because they can be collected without an invasive procedure for the recipient. Patients should ask about the exact tissue source, donor screening, cell passage and laboratory testing.

Wharton's Jelly is the connective tissue surrounding the blood vessels inside the umbilical cord. MSCs isolated from this tissue are donor-derived and are used in some physician-supervised regenerative programmes. Important considerations include donor eligibility, sterility testing, cell identity, viability and manufacturing standards.

Bone marrow-derived cells are collected from the patient's bone marrow, usually through a medically supervised aspiration procedure. The collected material may contain several cell populations rather than one single cell type. Patients should understand the collection procedure, expected cell composition, processing method and recovery requirements.

Adipose-derived cells are obtained from the patient's own fat tissue through a collection procedure. Stromal vascular fraction, or SVF, may contain a mixture of different cells and supporting biological components. Processing methods, regulatory status, treatment protocols and evidence can differ significantly between providers.

Mesenchymal stromal cells and hematopoietic stem cells are different cell categories with different biological roles. MSCs are commonly associated with connective tissues and cell-signalling research, while HSCs form blood and immune cells. They should not be described or marketed as though they are interchangeable.

Fresh and cryopreserved cells can both be used within appropriately controlled clinical and laboratory systems. Quality depends on more than whether cells are fresh or frozen, including collection, transport, storage, thawing, viability and administration procedures. Ask the provider for product-specific quality information rather than relying on general claims.

Before considering any cell-based programme, patients should ask for clear information about the laboratory and product. Important areas include donor screening, sterility, cell identity, viability, passage number, storage, transport and batch documentation. Treatment should also include physician assessment, informed consent and an appropriate follow-up plan.